TG Therapeutics Inc (TGTX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and autoimmune diseases. The company develops two therapies, namely, TG-1101 (ublituximab) and TGR-1202 for the treatment of hematological malignancies. TG-1101 glycoengineered monoclonal antibody that targets a unique epitope on the B-lymphocyte CD20 antigen and TG-1202 is an orally available PI3K delta inhibitor. Its other product candidates include inhibitors of IRAK4 and anti-PD-L1 and anti-GITR antibodies. The company also offers products and technologies for in-licensing, partnership, acquisition and/or investment. TG Therapeutics is headquartered in New York City, New York, the US.

TG Therapeutics Inc (TGTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TG Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
TG Therapeutics and Novimmune Enter into Agreement 12
TG Therapeutics Enters into Research Agreement with Fast Forward 13
TG Therapeutics Enters into Agreement with University of Nebraska Medical Center 14
TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics 15
TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies 16
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 17
Licensing Agreements 19
TG Therapeutics Enters into Licensing Agreement with Jiangsu Hengrui 19
TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 21
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 23
TG Therapeutics Enters Into Licensing Agreement With Ildong Pharma For Ublituximab 24
TG Therapeutics Enters Into Licensing Agreement With LFB Biotechnologies And GTC Biotherapeutics For Ublituximab 25
Equity Offering 26
TG Therapeutics Raises USD57.5 Million in Underwritten Public Offering of Shares 26
TG Therapeutics Raises USD50 Million in Public Offering Of Common Stock 27
TG Therapeutics Completes Private Placement Of Shares For US$18 Million 28
TG Therapeutics Completes Underwriters Exercise Of Over-Allotment Option For Public Offering Of Shares For US$5.3 Million 29
Manhattan Pharma Completes Private Placement Of Shares For US$25 Million 31
TG Therapeutics Inc - Key Competitors 32
TG Therapeutics Inc - Key Employees 33
TG Therapeutics Inc - Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Nov 08, 2017: TG Therapeutics Provides Business Update and Reports Third Quarter 2017 Financial Results 35
Aug 09, 2017: TG Therapeutics Provides Business Update and Reports Second Quarter 2017 Financial Results 36
May 05, 2017: TG Therapeutics Provides Business Update and Reports First Quarter 2017 Financial Results 38
Mar 10, 2017: TG Therapeutics Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update 40
Corporate Communications 41
Jun 04, 2018: TG Therapeutics Names Adam Waldman As Chief Commercial Officer 41
Product News 42
06/26/2017: TG Therapeutics Recaps Data from Triple Combination Therapy Trials at the 22nd European Hematology Association Annual Congress 42
05/18/2017: TG Therapeutics Announces Clinical Data Presentations at the Upcoming 22nd European Hematology Association Annual Congress 44
Product Approvals 45
Jan 24, 2017: TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for the Treatment of Diffuse Large B-cell Lymphoma 45
Jan 09, 2017: TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for Treatment of Chronic Lymphocytic Leukemia 46
Clinical Trials 47
Jan 24, 2018: TG Therapeutics Announces Data Presentation at the Upcoming Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018 47
Dec 11, 2017: TG Therapeutics Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting 48
Dec 08, 2017: TG Therapeutics Recaps Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting 51
Nov 01, 2017: TG Therapeutics Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting 53
Oct 26, 2017: TG Therapeutics Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS ACTRIMS Meeting 55
Oct 16, 2017: TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial 56
Sep 05, 2017: TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial 57
Aug 10, 2017: TG Therapeutics Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial 58
Jun 15, 2017: TG Therapeutics Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma 59
May 23, 2017: TG Therapeutics Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial 60
Other Significant Developments 61
May 08, 2018: TG Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List Of Tables

List of Tables
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TG Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TG Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
TG Therapeutics and Novimmune Enter into Agreement 12
TG Therapeutics Enters into Research Agreement with Fast Forward 13
TG Therapeutics Enters into Agreement with University of Nebraska Medical Center 14
TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics 15
TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies 16
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 17
TG Therapeutics Enters into Licensing Agreement with Jiangsu Hengrui 19
TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 21
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 23
TG Therapeutics Enters Into Licensing Agreement With Ildong Pharma For Ublituximab 24
TG Therapeutics Enters Into Licensing Agreement With LFB Biotechnologies And GTC Biotherapeutics For Ublituximab 25
TG Therapeutics Raises USD57.5 Million in Underwritten Public Offering of Shares 26
TG Therapeutics Raises USD50 Million in Public Offering Of Common Stock 27
TG Therapeutics Completes Private Placement Of Shares For US$18 Million 28
TG Therapeutics Completes Underwriters Exercise Of Over-Allotment Option For Public Offering Of Shares For US$5.3 Million 29
Manhattan Pharma Completes Private Placement Of Shares For US$25 Million 31
TG Therapeutics Inc, Key Competitors 32
TG Therapeutics Inc, Key Employees 33
TG Therapeutics Inc, Subsidiaries 34

List Of Figures

List of Figures
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Petrol dd Ljubljana (PETG) - Oil & Gas - Deals and Alliances Profile

Petrol dd Ljubljana (Petrol dd) is an energy company. It markets and distributes oil and petroleum products, electricity, heat, merchandise, natural gas and liquefied petroleum gas (LPG). The company sells

USD 250 View Report

Naturgy Energy Group SA. (NTGY) - Oil & Gas - Deals and Alliances Profile

Naturgy Energy Group SA (Naturgy) formerly know as Gas Natural Fenosa, is an integrated gas and electric utility that carries out the exploration, development, liquefaction, regasification, transportation, storage, distribution and

USD 250 View Report

HLS Therapeutics Inc (HLS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

HLS Therapeutics Inc (HLS Therapeutics) is a pharmaceutical company that offers central nervous system and cardiovascular therapeutic products. The companys product includes clozaril, absorica, vascepa and trinomial. Its clozapine is

USD 250 View Report

Callitas Therapeutics Inc (LILY) - Medical Equipment - Deals and Alliances Profile

Callitas Therapeutics Inc (Callitas Therapeutics), formerly M Pharmaceutical Inc, is a drug discovery and development company that offers ground-breaking drug treatments and biomedical technologies. The companys products include weight management

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available